# Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients

> **NCT00221624** · PHASE3 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 131 (actual)

## Conditions studied

- HCV Infection
- Hepatitis C, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** ribavirin
- **DRUG:** amantadine

## Key facts

- **NCT ID:** NCT00221624
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2007-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00221624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00221624, "Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00221624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*